X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dna-damaging agents (685) 685
humans (430) 430
animals (280) 280
oncology (278) 278
biochemistry & molecular biology (222) 222
apoptosis (214) 214
index medicus (181) 181
dna damage (179) 179
cell biology (169) 169
p53 (143) 143
mice (139) 139
genetics & heredity (115) 115
expression (109) 109
cancer (106) 106
dna repair (106) 106
wild-type p53 (95) 95
antineoplastic agents - pharmacology (93) 93
tumor cells, cultured (91) 91
cell cycle (90) 90
tumor suppressor protein p53 - metabolism (89) 89
apoptosis - drug effects (88) 88
cell line, tumor (83) 83
female (82) 82
induction (81) 81
tumor suppressor protein p53 - genetics (80) 80
mutation (76) 76
ionizing-radiation (74) 74
protein (74) 74
cell line (70) 70
toxicology (67) 67
growth arrest (63) 63
in-vivo (63) 63
phosphorylation (62) 62
ultraviolet rays (61) 61
chemotherapy (57) 57
cisplatin - pharmacology (57) 57
gene (57) 57
molecular sequence data (57) 57
pharmacology & pharmacy (57) 57
rats (57) 57
male (56) 56
base sequence (54) 54
gene expression (54) 54
article (52) 52
cells, cultured (52) 52
mammalian-cells (52) 52
proteins (52) 52
cells (51) 51
dna damaging agents (51) 51
transfection (51) 51
repair (50) 50
research (47) 47
cisplatin (46) 46
dna (46) 46
activation (45) 45
dose-response relationship, drug (45) 45
genetic aspects (44) 44
signal transduction (44) 44
biotechnology & applied microbiology (43) 43
genes, p53 (43) 43
saccharomyces-cerevisiae (43) 43
dna damage - drug effects (41) 41
gene-expression (41) 41
tumor suppressor protein p53 - physiology (40) 40
cell survival - drug effects (39) 39
flow cytometry (38) 38
induced apoptosis (38) 38
oxidative stress (38) 38
saccharomyces cerevisiae - genetics (38) 38
cell cycle - drug effects (37) 37
messenger-rna (37) 37
nf-kappa-b (37) 37
rna, messenger - genetics (37) 37
analysis (36) 36
neoplasms - drug therapy (36) 36
cyclin-dependent kinase inhibitor p21 (35) 35
radiation (35) 35
transcription (35) 35
transcriptional activation (35) 35
biophysics (34) 34
escherichia-coli (34) 34
rna, messenger - metabolism (34) 34
apoptosis - physiology (33) 33
cell cycle proteins - metabolism (33) 33
cell-cycle (33) 33
enzyme inhibitors - pharmacology (33) 33
gamma rays (33) 33
in-vitro (33) 33
neurosciences (33) 33
time factors (33) 33
tumor-cells (33) 33
breast-cancer (32) 32
homologous recombination (32) 32
mutations (32) 32
genes (31) 31
nuclear proteins - metabolism (31) 31
ataxia-telangiectasia (30) 30
biology (30) 30
ionizing radiation (30) 30
transcription, genetic (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 05/2007, Volume 13, Issue 9, pp. 2728 - 2737
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 11/2009, Volume 8, Issue 11, pp. 2992 - 3000
Journal Article
Cancer Biology and Therapy, ISSN 1538-4047, 04/2010, Volume 9, Issue 7, pp. 514 - 522
MK-1775 is a potent and selective small molecule Wee1 inhibitor. Previously we have shown that it abrogated DNA damaged checkpoints induced by gemcitabine,... 
Checkpoint | DNA-damaging agents | Wee1 | Kinase inhibitor | 5-FU | MK-1775 | checkpoint | PHOSPHORYLATION | THYMIDYLATE SYNTHASE | KINASE | SENSITIVITY | MECHANISMS | G CHECKPOINT | kinase inhibitor | CHK1 | ONCOLOGY | CANCER CELL-LINES | CHECKPOINT ABROGATION | CYCLE
Journal Article
Haematologica, ISSN 0390-6078, 01/2018, Volume 103, Issue 1, pp. 80 - 90
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 30, pp. 3409 - 3415
Journal Article
ANTICANCER RESEARCH, ISSN 0250-7005, 04/2019, Volume 39, Issue 4, pp. 1813 - 1820
Background/Aim: Chemotherapy is an important first-line treatment for oesophageal squamous cell carcinoma (ESCC). However, there are few secondary options.... 
PARP inhibitor | OVARIAN-CANCER | COMBINATION | CHEMOTHERAPY | DNA damaging agents | BREAST-CANCER | 5-FLUOROURACIL | REPAIR | INHIBITION | CISPLATIN | ONCOLOGY | RESISTANCE | Oesophageal squamous cell carcinoma | HOMOLOGOUS RECOMBINATION | synergistic effect | Esophageal Squamous Cell Carcinoma - metabolism | Phosphorylation | Esophageal Squamous Cell Carcinoma - pathology | Humans | Cisplatin - pharmacology | Piperazines - pharmacology | Temozolomide - pharmacology | Esophageal Squamous Cell Carcinoma - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Drug Synergism | Phthalazines - pharmacology | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Cell Line, Tumor | DNA Damage | Histones - metabolism | Esophageal Squamous Cell Carcinoma - drug therapy | Irinotecan - pharmacology | Doxorubicin - pharmacology | Drugs | Biotechnology | Histone H2A | 5-Fluorouracil | DNA damage | Cytotoxicity | ADP | Doxorubicin | Accumulation | Anticancer properties | Synergistic effects | Antitumor agents | Ribose | Toxicity testing | Damage accumulation | Deoxyribonucleic acid--DNA | Squamous cell carcinoma | Poly(ADP-ribose) polymerase | Tumor cell lines | Cisplatin | Esophagus | Polymerase | Chemotherapy | Cell lines | Biomarkers | Antitumor activity | Temozolomide | Cancer
Journal Article
Mutation Research - Genetic Toxicology and Environmental Mutagenesis, ISSN 1383-5718, 11/2018, Volume 835, pp. 16 - 20
Many DNA damaging agents also react with RNA and protein, and could thus cause epigenetic as well as genotoxic changes. To investigate which DNA damaging... 
Epigenetics | Budding yeast | Sir-mediated gene silencing | DNA damaging agent | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | TOXICOLOGY | Methane | Epigenetic inheritance | RNA | Genes | DNA | Genetic research | Genetic engineering
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 08/2013, Volume 12, Issue 8, pp. 1442 - 1452
Inhibition of the DNA damage checkpoint kinase WEE1 potentiates genotoxic chemotherapies by abrogating cell-cycle arrest and proper DNA repair. However, WEE1... 
CYCLIN-DEPENDENT KINASES | CANCER-CELLS | DNA-DAMAGING AGENTS | GROWTH-INHIBITION | IN-VITRO | CHK1 | ONCOLOGY | GENOME INTEGRITY | GENE-EXPRESSION | S-PHASE | ANTITUMOR-ACTIVITY | Neoplasms - metabolism | Protein-Tyrosine Kinases - metabolism | Humans | Antineoplastic Agents - administration & dosage | Gene Knockdown Techniques | Cell Cycle Proteins - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Drug Evaluation, Preclinical | Protein-Serine-Threonine Kinases - metabolism | Disease Models, Animal | Pyrazoles - pharmacology | DNA Damage - drug effects | Membrane Proteins - genetics | Pyrimidines - administration & dosage | Protein-Serine-Threonine Kinases - genetics | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Pyrazoles - administration & dosage | Animals | Tumor Burden - drug effects | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Cell Cycle - drug effects | Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal Article